In confirmation of this targeting, Manso and colleagues have examined the impact of IgG1 and IgG4 anti-CNTN1 antibodies isolated from CIDP patients on nerve structure [98]. This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.